IP Verse

Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan

PatentPatent Analysis

EP2861210

IPSEN BIOPHARM
Application Number
EP13731230A
Filing Date
Jun 12, 2013
Status
Revoked
May 20, 2022
Grant Date
May 3, 2017
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3796929B1
EP3758611B1
EP3266456B1

Bibliography

The patent EP2861210B1 was granted to Ipsen Biopharm on May 3, 2017 following the initial filing on Jun 12, 2013 under the application number EP13731230A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSFeb 5, 2018ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents